RENO-60 Drug Patent Profile
✉ Email this page to a colleague
When do Reno-60 patents expire, and when can generic versions of Reno-60 launch?
Reno-60 is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in RENO-60 is diatrizoate meglumine. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the diatrizoate meglumine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RENO-60?
- What are the global sales for RENO-60?
- What is Average Wholesale Price for RENO-60?
Summary for RENO-60
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 32 |
| Patent Applications: | 890 |
| DailyMed Link: | RENO-60 at DailyMed |
Pharmacology for RENO-60
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for RENO-60
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | RENO-60 | diatrizoate meglumine | INJECTABLE;INJECTION | 010040-016 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
